Renal Dysfunction With Low to Intermediate Dose Methotrexate in Acute Lymphoblastic Leukemia Treatment
N/A
21 Years
Both
Leukemia, Renal Toxicity
Trial Information
Renal Dysfunction With Low to Intermediate Dose Methotrexate in Acute Lymphoblastic Leukemia Treatment
OBJECTIVES:
- Examine the incidence of renal dysfunction in children and young adults being treated
for acute lymphoblastic leukemia with low- to intermediate-dose methotrexate.
OUTLINE: Medical charts are reviewed to obtain the following information: gender, age,
diagnosis, regimen, day of therapy, renal function, creatinine level, mucositis, skin
sloughing, methotrexate level at highest level, and number of days after intravenous
methotrexate.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of acute lymphoblastic leukemia
- Receiving low- to intermediate-dose methotrexate or received treatment
(chemotherapy and/or radiation) at Vanderbilt Children's Hospital
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Incidence of renal dysfunction in children and young adults being treated for acute lymphoblastic leukemia with low- to intermediate-dose methotrexate
Safety Issue:
No
Principal Investigator
Pinki Prasad, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Vanderbilt-Ingram Cancer Center
Authority:
United States: Federal Government
Study ID:
CDR0000652517
NCT ID:
NCT00993135
Start Date:
December 2008
Completion Date:
Related Keywords:
- Leukemia
- Renal Toxicity
- renal toxicity
- childhood acute lymphoblastic leukemia
- adult acute lymphoblastic leukemia
- Leukemia
- Leukemia, Lymphoid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Kidney Diseases
Name | Location |
|---|---|
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee 37232-6838 |
| Vanderbilt-Ingram Cancer Center - Cool Springs | Nashville, Tennessee 37064 |
